Steven G. Deeks, MD, is a Professor of Medicine in Residence at the University of California, San Francisco (UCSF) and a faculty member in the Division of HIV, Infectious Diseases and Global Medicine at Zuckerberg San Francisco General Hospital. Dr. Deeks has been engaged in HIV research and clinical care since 1993. He is a recognized expert on HIV-associated immune dysfunction and its impact on HIV persistence (the “reservoir”) and health during antiretroviral therapy. Dr. Deeks has published over 500 peer-review articles, editorials and invited reviews on these and related topics. He has been the recipient of several NIH grants, and one of the principal investigators of DARE (the Delaney AIDS Research Enterprise), which is an NIH-funded international Collaboratory aimed at developing therapeutic interventions to cure HIV infection. He a member of the Board of Directors for the UCSF-based amfAR Institute for HIV Cure Research. He is the co-chair of the “Towards an HIV Cure” International Working Group and a former co-chair of the NIH Office of AIDS Research Toward a Cure Planning Group. He was elected to the American Society for Clinical Investigation (ASCI) and Association of American Physicians (AAP), and serves on the Scientific Advisory Board for Science Translational Medicine and the Advisory Board of EBioMedicine. In addition to his clinical and translational investigation, Dr. Deeksmaintains a primary care clinic for HIV infected patients. He is a former member of the Office of AIDS Research Advisory Council (ORAC) and of the Department on Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents.
Mr. Joseph DeAngelo is a founding Scientist of BioSavita. Mr. DeAngelo is also the founder and CEO of Cereva Biotechnology Corp whose mission is to engineer yeast for the production ofanimal feed and human food. Mr. DeAngelo is an inventor of several issued patents on yeast technology and nitric oxide biology. His work on genetic engineering of yeast is focused on the expression of heterologous proteins, secretion, and post-translational modification, particularly on glycosylation. After Mr. DeAngelo’s graduation from MIT, he co-founded a yeast biotechnology company, Strohtech/Apex Bioscience that focused on yeast production of recombinant hemoglobin for use as a blood substitute. There he led a group of 40 scientists, including groups in molecular biology, fermentation, and downstream processing. He was Vice-president of Research and Chief Scientific Officer for Apex Bioscience, the US subsidiary of Curacyte AG and a member of Curacyte Vorstand. Under his direction, Apex’s lead product, PHP, a hemoglobin-based nitric oxide scavenger, was developed from pre-phase 1 to phase 3 clinical trials. He was a shareholder’s technical liaison in Delta Biotechnology, a UK company that developed a process for the secretion of recombinant serum albumin in yeast. Delta went on to develop HSA fusion proteins. One of which, Albuferon, was developed by Human Genome Sciences. Mr. DeAngelo received both his undergraduate and graduate training at the Massachusetts Institute of Technology.
Dr. Michael Feldhaus has extensive experience building biotech companies from ground zero into fully integrated teams delivering biologics to the clinic. He is inventor of several patents on antibody discovery, humanization, and development. He is expert in S. cevervisiae yeast display technology, and he developed 3 antibody discovery platforms in Saccharomyces yeast at Pacific Northwest National Laboratory and at Adimab LLC. Dr. Feldhaus’scareer development over the last 20 years emphasized antibody discovery, optimization and humanization with a focus toward clinical development of these entities. He managed multiple projects through GMP cell line development. He has also played key roles in engineering bi-specific antibodies, cytokine Fc fusions, and CART receptors. He has expertise in Project Management, Business Development, Technology Transfer, Preclinical development of biologics continues to be key in moving projects forward for Vaccine development at BioSavita. Analytical assessment of characteristics of biologics for clinical development is crucial in understanding the protein properties of biologics. Antibody discovery, protein engineering, and expression/production in yeast, HEK and CHO all help develop new tools and systems to produce novel biologics. Developing antibody discovery systems for industrial use, designing and building synthetic and natural immune libraries both required attention to detail and understanding the requirements of industry that differ significantly from an academic setting. Dr. Feldhaus is currently an advisor to multiple biologics companies including a company for (GM-CSF) LEUKINE production in yeast.
Prof. Fred Winston is a Professor of Genetics at Harvard Medical School. He is an expert in the areas of yeast genetics, transcriptional control, and chromatin structure. Prof. Winston began studies of yeast genetics and molecular biology as a postdoctoral fellow with Dr. Gerald Fink. For over 20 years, his laboratory at Harvard has used yeast genetics to identify and study proteins critical for normal gene expression. These pioneering studies have led to several new insights concerning the roles of general transcription factors, chromatin remodeling complexes, histone proteins, and transcription elongation. Prof. Winston has been advisor for Dr. Motwani’s scientific team at Apex Bioscience and later at BioSavita. He received his Ph.D. in Biology from the Massachusetts Institute of Technology.
Dr. Javaud is expert in glycobiology of S. cerevisiae yeast. He was co-founder, CEO and Chairman of the Board of GlycodeS.A.S. (France), a VC funded innovative startup company focused on generating yeast with humanized glyco-engineering to produce homogenous glycosylation of therapeutic products. He is a co- inventor of three patents in glyco-engineering of yeast. He was successful in licensing deals with major international biopharma companies. He received his Ph. D. in Molecular Biotechnology from University of Limoges in France and his Executive MBA at HEC School of Management (Paris)/Babson College (Boston) with focus on Entrepreneurship and Innovation. Currently, Dr. Christophe Javaud is in charge ofstrategic alliance management at Gustave Roussy Cancer center, the premier European Cancer Centre.
Dr. Bramhill has over 25 years of experience as a senior scientist, licensing executive
and director of technical workshops in major pharma, biotech and investment funds.
Dr. Bramhill has expertise in Virus biology. (SARS, HIV, Influenza), vaccine discovery and
development (HIV, Shingrix), antibody drug conjugates, bi-specific antibody libraries,
and peptide conjugation and engineering. At Merck, Dave set up the antibody
discovery with focus on project to neutralize HIV. His research experience includes therapeutic monoclonal antibodies, phage display, assay development, vaccines, immunology, antiviral, antibacterial, cancer research. David has expertise in protein chemistry, expression, purification, enzymology, whole cell and biochemical HTS, molecular biology, cell biology, phage display and genomics. He managed out-licensing programs covering platform biologics technologies, including Pichia yeast expression technology and FreE coli TM endotoxin-free bacterial expression systems. He is expert in antibody technologies and assay development. Dave has done extensive work on antibody engineering, Bi-specific antibodies, library variant designs
for various scaffolds and proteins, andused most display technologies known. He also
worked on evaluation of manufacturing cell lines and downstream methods for antibody
production. Dr. Bramhill has been independent consultant from 2004. During the time consulting, Dave has been recruited to conduct 1 or 2 day workshops at numerous international
conferences (as well as in-house courses and review programs as a KOL on antibody
technologies and related biologics. Dave received his BA nd MA from Cambridge
University (UK) and Ph.D. from Newcastle University in UK. He completed his
postdoctoral research at Stanford University under Nobel laureate Prof Arthur Kornberg.
Copyright © 2023 BioSavita, Inc - All Rights Reserved.